# A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation

> **NCT02981472** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 192 (actual)

## Conditions studied

- Thrombosis

## Interventions

- **DRUG:** Apixaban
- **DRUG:** Vitamin K Antagonist (VKA)
- **DRUG:** Low Molecular Weight Heparin (LMWH)

## Key facts

- **NCT ID:** NCT02981472
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-19
- **Primary completion:** 2021-10-18
- **Final completion:** 2021-10-18
- **Target enrollment:** 192 (ACTUAL)
- **Last updated:** 2022-10-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02981472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02981472, "A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02981472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*